Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.
What happened Shares of Moderna (NASDAQ: MRNA) had slid 4.2% lower at 11:26 a.m. ET on Tuesday after being down as much as 5.8% earlier in the day. The company didn't announce any negative news. However, there were a couple of factors that could be behind the decline.
Shares of Moderna (NASDAQ: MRNA) rose 3.3% on Monday after health regulators in the U.K. authorized the biopharmaceutical leader's bivalent COVID-19 vaccine booster for use in adults. Moderna's updated vaccine targets the original coronavirus strain and the currently fast-spreading omicron variants. On Monday, the Medicines and Healthcare products Regulatory Agency (MHRA) said the new bivalent booster meets its "standards of safety, quality, and effectiveness."